From The Editor | April 8, 2020

Adaptimmune, Cell & Gene On COVID-19's Impact On The Cell And Gene Sector

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

In this video, Michael Blackton, VP QA CMC and John Lunger Chief Patient Supply Officer at Adaptimmune talked to Cell & Gene’s Chief Editor, Erin Harris, about COVID-19’s impact on the cell and gene sector.

Adaptimmune is an autologous cell therapy company that develops novel cell therapies for people with cancer. You’ll see them discuss how COVID-19 has impacted the cell and gene sector to date and how the sector responded to the pandemic. They discussed the sector before COVID-19 and what “the after” looks like for CGTs. And, of course, what this pandemic means for the patient.